Haier Biomedical Science and Technology Innovation Board application accepted, IoT biotechnology becomes an innovative highlight

2019-04-03 19:20 Source: Tonghuashun Finance

Original title: Haier Biomedical Science and Technology Innovation Board application accepted, IoT biotechnology becomes an innovative highlight

On the evening of April 2nd, the Shanghai Stock Exchange disclosed the list of newly listed companies on the Science Innovation Board, including Shenzhen Chuangxin Laser Co., Ltd., Shenlian Biopharmaceutical (Shanghai) Co., Ltd., Suzhou Tianzhun Technology Co., Ltd., Qingdao Haier (600690) Biomedical Co., Ltd., Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd., and Juchen Semiconductor Co., Ltd. So far, the number of companies accepted for listing on the Science and Technology Innovation Board has increased to 37, among which Haier Biomedical is the second company from Qingdao and Shandong to apply for listing on the board.

Pre disclosed information shows that Haier Biomedical's main business begins with the research and development, production, and sales of low-temperature storage devices for biomedicine. It is a comprehensive biotechnology solution service provider based on the transformation of the Internet of Things. The company mainly provides comprehensive low-temperature storage solutions for biological sample banks, blood safety, vaccine safety, drug and reagent safety, and other scenarios.

Examining the technological "gold content" of companies accepted by the Science and Technology Innovation Board, their core technologies, quantity, and awards have become important indicators of industry status and sustainable development.

According to publicly available information, Haier Biomedical can provide low-temperature storage products for biomedicine covering the entire temperature range of -196 ℃ to 8 ℃, with the main revenue reflected in the sales of low-temperature storage equipment. The company and its subsidiaries have a total of 263 approved and pending applications, including 65 inventions; Among them, 177 have been approved, including 31 inventions.

In terms of technology, Haier Biomedical has broken through foreign monopolies and advanced low-temperature technology in biomedicine, winning the National Science and Technology Progress Award; And successfully industrialized the technology, winning the "National High tech Industrialization Ten Year Achievement Award" issued by the National Development and Reform Commission. As of now, it ranks first among domestic brand companies in terms of market share and has become a long-term procurement supplier for the World Health Organization (WHO) and UNICEF.

It is reported that in response to major national needs such as blood and vaccine safety, Haier Biomedical has deeply integrated low-temperature storage technology with new generation information technology and applied it to hot issues of concern to the people, achieving breakthroughs in scenarios such as vaccines, blood, and biological samples.

The IoT intelligent vaccine inoculation solution created by Haier Biomedical achieves full traceability from the source of vaccines to the inoculation process. Currently, it covers 100 community service centers across China, including Tianjin, Henan, Guangzhou, and Inner Mongolia, and has provided safe vaccination services for one million children nationwide. The IoT intelligent blood safety solution has built a platform ecosystem for monitoring and tracing blood information throughout the entire process from "blood vessels" to "blood vessels" and from the blood collection end to the blood use end. At the same time, it has moved the blood bank to clinical blood use points such as emergency departments and ambulances, reducing blood collection time from 20 minutes to 1 minute. This has won valuable time for saving patients' lives, ensuring blood safety and quality, and reducing unreasonable blood use.

The prospectus also shows Haier Biomedical's future development plan, which will be committed to building the ability to provide comprehensive biotechnology solutions, further consolidating the technology and product foundation, exploring medical IoT solutions, and gaining greater growth space. Return to Sohu to view more

Responsible Editor: